Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MDH2 | P40926 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | DNA2 | P51530 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551347 | 0.73 | CFTR (0.67) | KDM4ECYP1A2HSD17B10ALDH1A1HPGD | |
| SCHEMBL377150 | 0.73 | CFTR (0.67) | KDM4ECYP1A2HSD17B10ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL29766716 | 0.71 | CFTR (0.65) | KDM4ECYP1A2HSD17B10ALDH1A1HPGD | |
| SCHEMBL9319718 | 0.71 | KDM4E (0.59) | KDM4ECYP1A2HSD17B10ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL9046989 | 0.71 | CFTR (0.65) | KDM4ECYP1A2HSD17B10ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL30585295 | 0.71 | CFTR (0.65) | KDM4ECYP1A2HSD17B10ALDH1A1HPGD | |
| SCHEMBL2978428 | 0.70 | KDM4E (0.67) | KDM4ECYP1A2HSD17B10ALDH1A1HPGD | |
| SCHEMBL20562057 | 0.69 | F7 (0.46) | KDM4ECYP1A2HSD17B10ALDH1A1HPGD | |
| SCHEMBL25189120 | 0.69 | KDM4E (0.69) | KDM4ECYP1A2HSD17B10ALDH1A1HPGD | |
| SCHEMBL2807362 | 0.69 | KDM4E (0.56) | KDM4ECYP1A2HSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 721 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464243-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL SCIENT IND RES (IN) | 2025-02-12 | — | — | EP | claimed |
| CN-113735769-B | Quinolinone alkaloid derivative containing acylhydrazone structure at 3-position and preparation method and application thereof | 太原理工大学 | 2023-02-28 | — | — | CN | claimed |
| CN-113461612-B | Quinolone tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2022-10-14 | — | — | CN | claimed |
| US-11274081-B2 | Process for the synthesis of ivacaftor | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-03-15 | — | — | US | claimed |
| CN-113735769-A | Quinolinone alkaloid derivative containing acylhydrazone structure at 3-position and preparation method and application thereof | 太原理工大学 | 2021-12-03 | — | — | CN | claimed |
| CN-113461612-A | Quinolone tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2021-10-01 | — | — | CN | claimed |
| US-20200325104-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-10-15 | — | — | US | claimed |
| US-20160280654-A1 | Solid Forms of Ivacaftor and Processes for the Preparation Thereof | THE BANK OF NOVA SCOTIA (CA) | 2016-09-29 | — | — | US | claimed |
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2026-04-23 | — | — | US | disclosed |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMA (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4218754-B1 | VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078136-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| CN-1346271-A | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA UK LTD (SE) | 2002-04-24 | — | — | CN | disclosed |
| US-20020031834-A1 | Fluorescent magnesium indicators | THE GOVERNMENT OF THE UNITED STATES | 2002-03-14 | — | — | US | disclosed |
| US-4822801-A | 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivative as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1989-04-18 | — | — | US | disclosed |
| EP-0028698-B1 | QUINOLINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS | Tanabe Seiyaku Co., Ltd. (JP) | 1982-12-22 | — | — | EP | disclosed |
| US-4327101-A | Quinoline compound useful as antibacterial agents in warm-blooded animals | TANABE SEIKAKU CO., LTD. (JP) | 1982-04-27 | — | — | US | disclosed |
| EP-0028698-A1 | Quinoline compounds, process for their preparation, and pharmaceutical compositions | Tanabe Seiyaku Co., Ltd. (JP) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274081-B2 | Process for the synthesis of ivacaftor | IDO1, IDO2, SLC10A2 | KDM4E 1575/4885CYP1A2 85/4885HSD17B10 301/4885 |
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, CLCN2, SCNN1B | KDM4E 3749/4885CYP1A2 2899/4885HSD17B10 4208/4885 |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SLC26A3, SLC26A4 | KDM4E 3921/4885CYP1A2 2440/4885HSD17B10 1617/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | KDM4E 1147/4885CYP1A2 1483/4885HSD17B10 2056/4885 |
| US-20200325104-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | IDO1, SLC10A2, IDO2 | KDM4E 1668/4885CYP1A2 101/4885HSD17B10 218/4885 |
| US-20260078136-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1A | KDM4E 2582/4885CYP1A2 2062/4885HSD17B10 4368/4885 |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | CFTR, ABCC2, ABCC8 | KDM4E 2948/4885CYP1A2 2805/4885HSD17B10 4694/4885 |
| US-20160280654-A1 | Solid Forms of Ivacaftor and Processes for the Preparation Thereof | PCSK9, SLC10A1, VKORC1 | KDM4E 3277/4885CYP1A2 274/4885HSD17B10 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.